Literature DB >> 26575262

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS.

Touraj Shokati1, Nicholas Bodenberger1, Holly Gadpaille1, Björn Schniedewind1, Alexander A Vinks2, Wenlei Jiang3, Rita R Alloway4, Uwe Christians5.   

Abstract

The calcineurin inhibitor tacrolimus is the cornerstone of most immunosuppressive treatment protocols after solid organ transplantation in the United States. Tacrolimus is a narrow therapeutic index drug and as such requires therapeutic drug monitoring and dose adjustment based on its whole blood trough concentrations. To facilitate home therapeutic drug and adherence monitoring, the collection of dried blood spots is an attractive concept. After a finger stick, the patient collects a blood drop on filter paper at home. After the blood is dried, it is mailed to the analytical laboratory where tacrolimus is quantified using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) in combination with a simple manual protein precipitation step and online column extraction. For tacrolimus analysis, a 6-mm disc is punched from the saturated center of the blood spot. The blood spot is homogenized using a bullet blender and then proteins are precipitated with methanol/0.2 M ZnSO4 containing the internal standard D2,(13)C-tacrolimus. After vortexing and centrifugation, 100 µl of supernatant is injected into an online extraction column and washed with 5 ml/min of 0.1 formic acid/acetonitrile (7:3, v:v) for 1 min. Hereafter, the switching valve is activated and the analytes are back-flushed onto the analytical column (and separated using a 0.1% formic acid/acetonitrile gradient). Tacrolimus is quantified in the positive multi reaction mode (MRM) using a tandem mass spectrometer. The assay is linear from 1 to 50 ng/ml. Inter-assay variability (3.6%-6.1%) and accuracy (91.7%-101.6%) as assessed over 20 days meet acceptance criteria. Average extraction recovery is 95.5%. There are no relevant carry-over, matrix interferences and matrix effects. Tacrolimus is stable in dried blood spots at RT and at +4 °C for 1 week. Extracted samples in the autosampler are stable at +4 °C for at least 72 hr.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26575262      PMCID: PMC4692696          DOI: 10.3791/52424

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  46 in total

1.  Ion suppression effects in liquid chromatography-electrospray-ionisation transport-region collision induced dissociation mass spectrometry with different serum extraction methods for systematic toxicological analysis with mass spectra libraries.

Authors:  Claudia Müller; Patrick Schäfer; Mylène Störtzel; Susanne Vogt; Wolfgang Weinmann
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2002-06-15       Impact factor: 3.205

2.  A survey of apparent blood volumes and sample geometries among filter paper bloodspot samples submitted for lead screening.

Authors:  Heather R Peck; Denise M Timko; James D Landmark; Douglas F Stickle
Journal:  Clin Chim Acta       Date:  2008-10-30       Impact factor: 3.786

Review 3.  PharmGKB summary: cyclosporine and tacrolimus pathways.

Authors:  Julia M Barbarino; Christine E Staatz; Raman Venkataramanan; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2013-10       Impact factor: 2.089

4.  Quality assessment issues of new immunosuppressive drugs and experimental experience.

Authors:  D W Holt; K Jones; T Lee; P Stadler; A Johnston
Journal:  Ther Drug Monit       Date:  1996-08       Impact factor: 3.681

5.  FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.

Authors:  T Kino; H Hatanaka; M Hashimoto; M Nishiyama; T Goto; M Okuhara; M Kohsaka; H Aoki; H Imanaka
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

Review 6.  Current issues in pediatric transplantation.

Authors:  D A Kelly
Journal:  Pediatr Transplant       Date:  2006-09

7.  Simultaneous measurement of cyclosporin A and tacrolimus from dried blood spots by ultra high performance liquid chromatography tandem mass spectrometry.

Authors:  Edward Hinchliffe; Joanne E Adaway; Brian G Keevil
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-05-20       Impact factor: 3.205

8.  A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.

Authors:  J D Pirsch; J Miller; M H Deierhoi; F Vincenti; R S Filo
Journal:  Transplantation       Date:  1997-04-15       Impact factor: 4.939

9.  Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection.

Authors:  B D Kahan; M Welsh; L Schoenberg; L P Rutzky; S M Katz; D L Urbauer; C T Van Buren
Journal:  Transplantation       Date:  1996-09-15       Impact factor: 4.939

Review 10.  Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Authors:  Uwe Christians; Wolfgang Jacobsen; Leslie Z Benet; Alfonso Lampen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

View more
  6 in total

1.  A Nucleic Acid Nanostructure Built through On-Electrode Ligation for Electrochemical Detection of a Broad Range of Analytes.

Authors:  Subramaniam Somasundaram; Christopher J Easley
Journal:  J Am Chem Soc       Date:  2019-07-09       Impact factor: 15.419

2.  Advantages and Challenges of Dried Blood Spot Analysis by Mass Spectrometry Across the Total Testing Process.

Authors:  Rosita Zakaria; Katrina J Allen; Jennifer J Koplin; Peter Roche; Ronda F Greaves
Journal:  EJIFCC       Date:  2016-12-01

3.  Validation of a Capillary Dry Blood Sample MITRA-Based Assay for the Quantitative Determination of Systemic Tacrolimus Concentrations in Transplant Recipients.

Authors:  Nasrullah Undre; Ian Dawson; Varuna Aluvihare; Nassim Kamar; Faouzi Saliba; Nicholas Torpey; Swapneel Anaokar; Gbenga Kazeem; Imran Hussain
Journal:  Ther Drug Monit       Date:  2021-06-01       Impact factor: 3.681

4.  Quantitation of Tacrolimus in Human Whole Blood Samples Using the MITRA Microsampling Device.

Authors:  Nasrullah Undre; Imran Hussain; John Meijer; Johannes Stanta; Gordon Swan; Ian Dawson
Journal:  Ther Drug Monit       Date:  2021-06-01       Impact factor: 3.681

5.  A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study.

Authors:  S Tremblay; V Nigro; J Weinberg; E S Woodle; R R Alloway
Journal:  Am J Transplant       Date:  2016-08-02       Impact factor: 8.086

6.  A next-generation newborn screening pilot study: NGS on dried blood spots detects causal mutations in patients with inherited metabolic diseases.

Authors:  F Boemer; C Fasquelle; S d'Otreppe; C Josse; V Dideberg; K Segers; V Guissard; V Capraro; F G Debray; V Bours
Journal:  Sci Rep       Date:  2017-12-15       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.